SEATTLE, Washington. and SUZHOU, China, March 8, 2022 /PRNewswire/ — ProfoundBio announced that preclinical data from its proprietary novel antibody-drug conjugate (ADC) pipeline and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held April 8 — 13, 2022. Presentations will highlight three late-stage preclinical programs utilizing ProfoundBio’s state-of-the-art ADC technology as well as advancements in the development of linker drugs. Additionally, ProfoundBio announced the appointment of Zhu ChenPhD, as Scientific Director.
“First of all, I am very pleased to have Dr. Chen join the management team of ProfoundBio. His world-class scientific background and drug development expertise will further enhance our ability to discover and develop ADCs, further accelerate the translation from lab to bedside of our new patented technology.” said Baiteng Zhao, PhD, CEO. “These presentations at the AACR Annual Meeting will demonstrate the continued and rapid advancement of our flagship programs as well as the potential of our ADC technology, I look forward to taking these programs to clinical trials to help cancer patients.
“ADCs are complex molecules that are increasingly integrated into the therapeutic arsenal of various cancers. We designed a new hydrophilic bonding platform that has improved physicochemical properties compared to conventional bonds; this platform can enable the use of drug-level hydrophobic payloads for antibody ratios (DARs) up to 8 and potentially higher, as dictated by the target biology, while maintaining favorable pharmacokinetic and pharmacodynamic characteristics in preclinical and potentially clinical models.” mentioned Zhu ChenPhD, scientific director.
Dr. Chen joins ProfoundBio with extensive experience in drug discovery and development in various disease areas. She was most recently Global Chief Medical Officer at Daiichi Sankyo, responsible for medical strategy and preparation for the launch of a number of compounds, including datopotamab deruxtecan. His previous roles include Global Medical Lead at Celgene, responsible for the medical activities and launch of several actives in hematological malignancies, and Discovery/Early Development Lead at Merck for several programs. Dr. Chen received his BS in Biochemistry and Molecular Biology from Peking University and his Ph.D. in the pharmacology and genetics of University of Texas Southwestern Medical Center at Dallas. She did her post-doctoral training at rockefeller university.
PRO1184 is an ADC composed of a novel proprietary antibody against folate receptor alpha conjugated to the exatecan payload via a novel hydrophilic linker. PRO1184 showed an encouraging preclinical profile on pharmacokinetics, PD, efficacy in multiple tumor types including NSCLC and ovarian cancer, and was well tolerated in a pilot safety study of non-human primates. PRO1184 is a promising candidate to be advanced to the clinic.
A poster entitled “PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, shows robust anti-tumor activity in mouse carcinoma models” will be presented on April 11, 2022 09:00 — 12:30 p.m.
PRO1160 is an ADC composed of a novel proprietary antibody against CD70 conjugated to the exatecan payload via a novel hydrophilic linker. PRO1160 produced a robust antitumor effect in preclinical solid tumor and lymphoma models while maintaining similar PK characteristics to the parental mAb in rats and was well tolerated in a pilot non-human primate safety study. PRO1160 could be an interesting molecule for further development in various cancers.
A poster titled “PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin’s lymphoma” will be presented on April 11, 2022 1:30 p.m. — 5 p.m.
PRO1102 is an ADC composed of trastuzumab conjugated to the exatecan payload via a novel hydrophilic linker. PRO1102 exhibited excellent PK and PD characteristics in preclinical models, was more potent than conventional trastuzumab-based ADCs in vivo, especially in models with moderate or low HER2 expression, and was well tolerated in clinical trials. preliminary evaluation in rodents. The results highlighted the unparalleled potential of the novel linker-drug (LD) platform.
A poster entitled “The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity” will be presented on April 11, 2022 1:30 p.m. — 5:00 p.m..
The new LDs (based on Exatecan, MMAE or Eribulin payloads) when conjugated to a tool antibody confer excellent physicochemical properties and favorable PK/PD characteristics compared to reference ADCs with a conventional platform in preclinical models. Along with the tolerability assessment reported in the accompanying presentations, the results showed that the novel LDs can be broadly applied to the discovery and development of novel ADCs with a potentially extended therapeutic index in the clinic.
A poster entitled “The new ADC platform offers promising in vivo activity and safety” will be presented on April 11, 2022 09:00 — 12:30 p.m.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapies with curative potential for cancer patients. Relying on innovative technological platforms, ProfoundBio has developed a pipeline composed of several drug candidates targeting solid tumors which are currently in the discovery and preclinical development phase. ProfoundBio operates both in the large Seattle region, WA, USA and Suzhou, China.
For more information, please visit www.profondbio.com.
Email: [email protected]
Show original content:https://www.prnewswire.com/news-releases/profoundbio-to-highlight-programs-and-technology-at-aacr-2022-annual-meeting-welcomes-zhu-chen-phd-as-chief-scientific- agent-301497996.html